Țară: Armenia
Limbă: engleză
Sursă: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
flecainide acetate
Alkaloid AD Skopje
C01BC04
flecainide acetate
50mg
tablets
(30/3x10/) in blister
Prescription
Registered
2021-08-19
Felkarid 50 mg and 100 mg tablets Summary of Product Characteristics SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Felkarid 50 mg tablets Felkarid 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg or 100 mg flecainide acetate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Felkarid 50 mg tablets White to off-white, round, biconvex tablets with diameter 7 mm. Felkarid 100 mg tablets White to off-white, round, biconvex tablets with diameter 9 mm and score line on one side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of - AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways. - Symptomatic sustained ventricular tachyarrhythmia. - Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms, where these are resistant to other therapy or when other treatment has not been tolerated. - Paroxysmal atrial arrhythmias (atrial fibrillation, flutter and tachycardia) in patients with disabling symptoms when treatment need has been established. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects. Flecainide Acetate tablets can be used for the maintenance of normal rhythm following conversion by other means. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Initiation of flecainide acetate therapy and dose adjustments should be made under medical supervision and monitoring of ECG and plasma level. Felkarid 50 mg and 100 mg tablets Summary of Product Characteristics Hospitalization could be necessary during such procedures for certain patients, especially for patients with life-threatening ventricular arrhythmias. These decisions should be made under supervision of specialist. In patients with an underlying organic cardiomyopathy and especially those wit Citiți documentul complet